Literature DB >> 17668375

Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1.

Ophélia Maertens1, Sofie De Schepper, Jo Vandesompele, Hilde Brems, Ine Heyns, Sandra Janssens, Frank Speleman, Eric Legius, Ludwine Messiaen.   

Abstract

Elucidation of the biological framework underlying the development of neurofibromatosis type 1 (NF1)-related symptoms has proved to be difficult. Complicating factors include the large size of the NF1 gene, the presence of several NF1 pseudogenes, the complex interactions between cell types, and the NF1-haploinsufficient state of all cells in the body. Here, we investigate three patients with distinct NF1-associated clinical manifestations (neurofibromas only, pigmentary changes only, and association of both symptoms). For each patient, various tissues and cell types were tested with comprehensive and quantitative assays capable of detecting low-percentage NF1 mutations. This approach confirmed the biallelic NF1 inactivation in Schwann cells in neurofibromas and, for the first time, demonstrated biallelic NF1 inactivation in melanocytes in NF1-related cafe-au-lait macules. Interestingly, both disease features arise even within a background of predominantly NF1 wild-type cells. Together, the data provide molecular evidence that (1) the distinct clinical picture of the patients is due to mosaicism for the NF1 mutation and (2) the mosaic phenotype reflects the embryonic timing and, accordingly, the neural crest-derived cell type involved in the somatic NF1 mutation. The study of the affected cell types provides important insight into developmental concepts underlying particular NF1-related disease features and opens avenues for improved diagnosis and genetic counseling of individuals with mosaic NF1.

Entities:  

Mesh:

Year:  2007        PMID: 17668375      PMCID: PMC1950809          DOI: 10.1086/519562

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  42 in total

1.  Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.

Authors:  Ophélia Maertens; Hilde Brems; Jo Vandesompele; Thomas De Raedt; Ine Heyns; Thorsten Rosenbaum; Sofie De Schepper; Anne De Paepe; Geert Mortier; Sandra Janssens; Frank Speleman; Eric Legius; Ludwine Messiaen
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

2.  Real-time quantitative allele discrimination assay using 3' locked nucleic acid primers for detection of low-percentage mosaic mutations.

Authors:  Ophélia Maertens; Eric Legius; Frank Speleman; Ludwine Messiaen; Jo Vandesompele
Journal:  Anal Biochem       Date:  2006-08-14       Impact factor: 3.365

3.  Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells.

Authors:  Amy M Munchhof; Fang Li; Hilary A White; Laura E Mead; Theresa R Krier; Amy Fenoglio; Xiaohong Li; Jin Yuan; Feng-Chun Yang; David A Ingram
Journal:  Hum Mol Genet       Date:  2006-04-28       Impact factor: 6.150

4.  Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.

Authors:  Thomas De Raedt; Ophélia Maertens; Magdalena Chmara; Hilde Brems; Ine Heyns; Raf Sciot; Elisa Majounie; Meena Upadhyaya; Sofie De Schepper; Frank Speleman; Ludwine Messiaen; Joris Robert Vermeesch; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2006-10       Impact factor: 5.006

5.  Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions.

Authors:  C Lopez Correa; H Brems; C Lázaro; X Estivill; M Clementi; S Mason; J L Rutkowski; P Marynen; E Legius
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

6.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

Authors:  L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

7.  Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.

Authors:  J L Rutkowski; K Wu; D H Gutmann; P J Boyer; E Legius
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

8.  Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind?

Authors:  Sofie De Schepper; Joachim Boucneau; Yves Vander Haeghen; Ludwine Messiaen; Jean-Marie Naeyaert; Jo Lambert
Journal:  Arch Dermatol Res       Date:  2006-02-15       Impact factor: 3.017

9.  Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR.

Authors:  Albert Rübben; Birke Bausch; Arjen Nikkels
Journal:  Mol Cancer       Date:  2006-09-10       Impact factor: 27.401

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  43 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 2.  Glial versus melanocyte cell fate choice: Schwann cell precursors as a cellular origin of melanocytes.

Authors:  Igor Adameyko; Francois Lallemend
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

3.  Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.

Authors:  Kevin P Boyd; Liyan Gao; Rui Feng; Mark Beasley; Ludwine Messiaen; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2010-06-03       Impact factor: 11.527

4.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

5.  In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells.

Authors:  Jennifer Allouche; Nathalia Bellon; Manoubia Saidani; Laure Stanchina-Chatrousse; Yolande Masson; Anand Patwardhan; Floriane Gilles-Marsens; Cédric Delevoye; Sophie Domingues; Xavier Nissan; Cécile Martinat; Gilles Lemaitre; Marc Peschanski; Christine Baldeschi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

Review 6.  Spinal reconstruction with pedicle screw-based instrumentation and rhBMP-2 in patients with neurofibromatosis and severe dural ectasia and spinal deformity: report of two cases and a review of the literature.

Authors:  Samuel K Cho; Geoffrey E Stoker; Keith H Bridwell
Journal:  J Bone Joint Surg Am       Date:  2011-08-03       Impact factor: 5.284

Review 7.  A genomic view of mosaicism and human disease.

Authors:  Leslie G Biesecker; Nancy B Spinner
Journal:  Nat Rev Genet       Date:  2013-05       Impact factor: 53.242

8.  SPRED proteins provide a NF-ty link to Ras suppression.

Authors:  Andrea I McClatchey; Karen Cichowski
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

9.  A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1.

Authors:  Sean Boley; Jennifer L Sloan; Alexander Pemov; Douglas R Stewart
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

10.  Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.

Authors:  Jon P Williams; Jianqiang Wu; Gunnar Johansson; Tilat A Rizvi; Shyra C Miller; Hartmut Geiger; Punam Malik; Wenling Li; Yoh-suke Mukouyama; Jose A Cancelas; Nancy Ratner
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.